We are part of the CSL Limited group of companies. See how we're Driven by Our Promise.
We collaborate with rare disease organizations to promote quality medical care and services.
We offer a variety of support programs and activities for the patients we serve.
We also aim to make sure that nothing holds you back from getting the therapies you need.
Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise.
A clinical trial is a research study that is done to find out if medical treatments can improve people’s health.
We work every day as if someone’s life depends on it, because it does.
We manufacture products to treat a number of rare diseases.
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL Behring.
Listen: Adapting to Change
Podcast features bleeding disorder experts in celebration of World Hemophilia Day.
Boosting Young Scientists
CSL Behring in Bern, Switzerland, awards scholarships to three top students.
NFL Players Cheer On Rare Disease Research
Uplifting Athletes presents $140,000 in research grants in the Young Investigator Draft.
Calling All Innovators
Your inventive idea could help the growing number of patients who rely on plasma-derived immunoglobulin.
What Is Convalescent Plasma?
Antibody-rich blood component may hold potential for those battling COVID-19.
Drafting Future Research Stars
On March 30, watch the Uplifting Athletes Young Investigator Draft to show support for scientists working to unravel rare dis…
Explainer: What Are Natural History Studies?
Natural history studies collect information from patients to better understand diseases, especially rare ones.
At the Heart of Innovation for Patients
Marburg, Germany’s vibrant R&D ecosystem creates hope for patients and CSL Behring’s future.
Expanding U.S. Cell- and Gene-Therapy Capability
CSL Behring’s planned laboratory in California will enhance innovation and collaboration near academic and research instituti…
Writing the Book on Sickle Cell Disease
Dr. Greg Kato, a CSL Behring medical expert, is among three editors of a new, deeply researched text on sickle cell disease. …
A Research Catalyst in Switzerland
A new partnership between CSL Behring and Biopôle takes shape, pairing the global biotech with one of the most dynamic life s…
Explainer: What Is PhRMA?
CSL CEO Paul Perreault recently joined the board of the Pharmaceutical Research and Manufacturers of America.
Popular search terms:
Americas
Asia Pacific
Europe
This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.
.png?h=900&w=1600&cropregion=0,0,1600,900&hash=B8048346D50708847AF3647685F4149F0C74D997)
